Skip to main content

Non-profit launches COVID-19 treatment and vaccine tracker with daily updates

There are a lot of global efforts underway to develop vaccines and treatments for COVID-19, including repurposing of existing drugs approved for use in treating other forms of coronavirus and respiratory diseases. Many of these efforts are just entering into the formal clinical study phase, which will be required before any treatment is certified for widespread use in patients diagnosed with the illness. Vaccines are still likely at least a year out from approvals, though some have already entered into clinical human trials at unprecedented speed owing to the unprecedented nature of the pandemic.

It’s definitely a challenge to keep up with all the existing efforts to pursue effective treatments and develop vaccines, but public health non-profit the Milken Institute has a new resource that aims to keep track of at least the efforts from leading research institutions and drug makers. Their COVID-19 treatment and vaccine tracker currently offers a list of nearly 60 treatments, as well as 43 vaccines in development.

This list details the type of treatment or vaccine being studied or developed, as well as their FDA-approved status (for other conditions – none have been approved specifically for treating COVID-19 to date). They also indicate who is doing the drug development or research, and what stage the research project is at (either pre-clinical or clinical). The table lists the source of funding, if available, as well as the anticipated timetable for the phases of the project if known. It provides sourcing for each, as well, including credible media sources, journals and the World Health Organization.

This kind of tracker is a good resource for anyone looking to keep tabs on the ongoing work that people are doing to take on COVID-19, though it’s a high-level view that is probably of most interest to other ongoing projects, as well as health and research professionals who might be able to assist in the development of these solutions, or to collaborate with partners. The Milken Institute says that it’s going to be updating the tracker daily at noon eastern with any additional fresh info from reliable sources.

As mentioned, even vaccines that are already in development, like the mRNA-based immune therapy that began human trials last week in the U.S., will take many months to come to market, and they still have to demonstrate their effectiveness, too. In the meantime, people should do everything they can to isolate and remain indoors in order to help buy time for the healthcare system to develop treatments that can mitigate the impact of the disease, and eventually, ways to introduce immunity in order to block its transmission.



from TechCrunch https://ift.tt/2wzejWu
Labels:

Comments

Post a Comment

Popular posts from this blog

The hidden cost of food delivery

Noah Lichtenstein Contributor Share on Twitter Noah Lichtenstein is the founder and managing partner of Crossover , a diversified private technology fund backed by institutional investors, technology execs and professional athletes and entertainers. More posts by this contributor What Studying Students Teaches Us About Great Apps I’ll admit it: When it comes to food, I’m lazy. There are dozens of great dining options within a few blocks of my home, yet I still end up ordering food through delivery apps four or five times per week. With the growing coronavirus pandemic closing restaurants and consumers self-isolating, it is likely we will see a spike in food delivery much like the 20% jump China reported during the peak of its crisis. With the food delivery sector rocketing toward a projected $365 billion by the end of the decade, I’m clearly not the only one turning to delivery apps even before the pandemic hit. Thanks to technology (and VC funding) we can get a ri...
Post a Comment
Read more

Political ‘fixer’ Bradley Tusk closes second fund on $70M

Tusk Venture Partners , the venture capital firm led by Bradley Tusk and managing partner Jordan Nof, has secured $70 million for its second flagship fund, the firm has confirmed to TechCrunch following a report by Fortune this morning. Fundraising for the effort began in January, when the pair filed paperwork with the U.S. Securities Exchange Commission for Tusk Venture Partners II. The firm and affiliated political advisory outfit Tusk Ventures, is behind a number of high-profile startups, including e-scooter ‘unicorn’ Bird, cryptocurrency exchange Coinbase and Ro, a direct-to-consumer healthcare business best known for selling erectile dysfunction medication. The New York-based firm, founded in 2011, previously raised  $36 million for its debut fund — capital it used to back medical marijuana delivery company  Eaze ; the marketplace for household service providers  Handy ; and fintech startup  Grove . Tusk, before launching Tusk Ventures, served a...
Post a Comment
Read more

New THC and CBD infused beverage company, Cann, joins the race to replace booze

Cann , a Los Angeles-based purveyor of CBD and THC-infused intoxicants, is rolling out its first major distribution through the venture-backed delivery service Eaze as it begins to hit the streets in California. The company founded by two former Bain consultants is the latest to take on the growing market for non-alcoholic intoxicants that use a combination of chemicals traditionally found in the marijuana plant to make their drinks. First dreamed up by Jake Bullock while attending business school at Stanford, Cann launched earlier this month at MedMen and is now selling its $30 multi-flavor six packs both in stores and through Eaze . The beverages come with 2 milligram dose of THC and 5milligrams of CBD per can. Bullock and his partner Luke Anderson met while both men were at Bain Consulting — and both have a background in consumer retail businesses. Bullock initially worked at the investment bank, Allen & Co., before moving over to Bain for consulting and finally settling in...
Post a Comment
Read more